A Single-Centre, Randomized, Double-Blind , Placebo Controlled, Dose Escalating Cross-Over Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Inhaled Doses of GSK610677 and Placebo in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs GSK 610677 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Status changed from recruiting to completed.
- 27 Oct 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 08 Jul 2008 New trial record.